Last edition
News about "HER2-negative"
EU Approves AstraZeneca's Etcamah Combination for ESR1-Mutated Advanced Breast Cancer
The European Commission has approved AstraZeneca’s Etcamah in combination with CDK4/6 inhibitors for ESR1-mutated ER-positive, HER2-negative advanced breast cancer, following Phase 3 data demonstrating a 56% reduction in the risk of disease progression or death.
HER2-negative | 24/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members